{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001239","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.811424+00:00","generated_at":"2026-05-28T03:09:05.204343+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones","bullets":["Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.","X4 receives €28.5M upfront; up to €226M in regulatory, commercial, sales milestones.","Escalating double-digit royalties up to mid-twenties on net sales in licensed territories.","X4 continues Phase 3 4WARD trial in chronic neutropenia; Norgine handles commercialization.","MAA for WHIM syndrome to be submitted to EMA shortly; mavorixafor has Orphan Drug Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001239","json":"https://secwatch.observer/filing/0001628280-25-001239.json","markdown":"https://secwatch.observer/filing/0001628280-25-001239.md","text":"https://secwatch.observer/filing/0001628280-25-001239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/0001628280-25-001239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/xfor-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:09:05.204343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}